These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 10691158)

  • 1. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.
    Wolffenbuttel BH; Gomis R; Squatrito S; Jones NP; Patwardhan RN
    Diabet Med; 2000 Jan; 17(1):40-7. PubMed ID: 10691158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.
    Patel J; Anderson RJ; Rappaport EB
    Diabetes Obes Metab; 1999 May; 1(3):165-72. PubMed ID: 11220295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus.
    Nolan JJ; Jones NP; Patwardhan R; Deacon LF
    Diabet Med; 2000 Apr; 17(4):287-94. PubMed ID: 10821295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC; Tsang LW; Sorensen JP; Cockram CS
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
    Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
    Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
    Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
    Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.
    Phillips LS; Grunberger G; Miller E; Patwardhan R; Rappaport EB; Salzman A;
    Diabetes Care; 2001 Feb; 24(2):308-15. PubMed ID: 11213884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
    Kumar S; Boulton AJ; Beck-Nielsen H; Berthezene F; Muggeo M; Persson B; Spinas GA; Donoghue S; Lettis S; Stewart-Long P
    Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes.
    Hanefeld M; Patwardhan R; Jones NP;
    Nutr Metab Cardiovasc Dis; 2007 Jan; 17(1):13-23. PubMed ID: 17174222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
    Betteridge DJ; Vergès B
    Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.
    Rosenstock J; Goldstein BJ; Vinik AI; O'neill MC; Porter LE; Heise MA; Kravitz B; Dirani RG; Freed MI;
    Diabetes Obes Metab; 2006 Jan; 8(1):49-57. PubMed ID: 16367882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus.
    Kerenyi Z; Samer H; James R; Yan Y; Stewart M
    Diabetes Res Clin Pract; 2004 Mar; 63(3):213-23. PubMed ID: 14757293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of rosiglitazone to existing sulfonylurea treatment in chinese patients with type 2 diabetes and exposure to hepatitis B or C.
    Zhu XX; Pan CY; Li GW; Shi HL; Tian H; Yang WY; Jiang J; Sun XC; Davies C; Chow WH
    Diabetes Technol Ther; 2003; 5(1):33-42. PubMed ID: 12725705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.
    Raskin P; Rappaport EB; Cole ST; Yan Y; Patwardhan R; Freed MI
    Diabetologia; 2000 Mar; 43(3):278-84. PubMed ID: 10768088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
    Raskin P; Rendell M; Riddle MC; Dole JF; Freed MI; Rosenstock J;
    Diabetes Care; 2001 Jul; 24(7):1226-32. PubMed ID: 11423507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
    Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
    Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
    Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.